Menu
Search
|

Menu

Close
X

Genprex Inc GNPX.OQ (NASDAQ Stock Exchange Capital Market)

1.79 USD
+0.01 (+0.56%)
As of 4:00 PM EDT
Previous Close 1.78
Open 1.80
Volume 1,668
3m Avg Volume 9,405
Today’s High 1.80
Today’s Low 1.78
52 Week High 19.40
52 Week Low 0.95
Shares Outstanding (mil) 0.33
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-0.884
FY17
-0.215
FY16
-0.194
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.55
Price to Sales (TTM)
vs sector
--
8.39
Price to Book (MRQ)
vs sector
--
5.27
Price to Cash Flow (TTM)
vs sector
--
24.12
Total Debt to Equity (MRQ)
vs sector
0.00
16.01
LT Debt to Equity (MRQ)
vs sector
0.00
11.33
Return on Investment (TTM)
vs sector
--
13.83
Return on Equity (TTM)
vs sector
--
15.25

EXECUTIVE LEADERSHIP

J. Rodney Varner
Chairman of the Board, Chief Executive Officer, Secretary, Since 2018
Salary: $75,000.00
Bonus: --
Julien Pham
President, Chief Operating Officer, Since 2018
Salary: $47,500.00
Bonus: --
Ryan Confer
Chief Financial Officer, Since 2016
Salary: $55,000.00
Bonus: --
John Bonfiglio
Director, Since 2019
Salary: --
Bonus: --
David Friedman
Director, Since 2012
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1601 Trinity St Bldg B
AUSTIN   TX   78712-1765

Phone: +1512.5377997
Site:

Genprex, Inc. is a clinical stage gene therapy company. The Company is focused on developing cancer-based upon its novel proprietary technology platform, including its initial product candidate, Oncoprex, immunogene therapy, or Oncoprex. The Company’s Oncoprex is lead product candidate, is the subject of an ongoing Phase I/II clinical trials at The University of Texas MD Anderson Cancer Center in patients with late stage non-small cell lung cancer, or NSCLC. Oncoprex gene therapy platform may also be effective with respect to other types of cancer, including breast, head and neck, renal cell (kidney), soft tissue cancer. The Company’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles. The Company’s Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis.

SPONSORED STORIES